JP4579246B2 - 乳癌を診断する方法 - Google Patents

乳癌を診断する方法 Download PDF

Info

Publication number
JP4579246B2
JP4579246B2 JP2006527766A JP2006527766A JP4579246B2 JP 4579246 B2 JP4579246 B2 JP 4579246B2 JP 2006527766 A JP2006527766 A JP 2006527766A JP 2006527766 A JP2006527766 A JP 2006527766A JP 4579246 B2 JP4579246 B2 JP 4579246B2
Authority
JP
Japan
Prior art keywords
breast cancer
cells
protein
brc
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006527766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506424A (ja
Inventor
祐輔 中村
豊雅 片桐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2007506424A publication Critical patent/JP2007506424A/ja
Application granted granted Critical
Publication of JP4579246B2 publication Critical patent/JP4579246B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2006527766A 2003-09-24 2004-08-10 乳癌を診断する方法 Expired - Fee Related JP4579246B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50557103P 2003-09-24 2003-09-24
PCT/JP2004/011741 WO2005029067A2 (en) 2003-09-24 2004-08-10 Method of diagnosing breast cancer

Publications (2)

Publication Number Publication Date
JP2007506424A JP2007506424A (ja) 2007-03-22
JP4579246B2 true JP4579246B2 (ja) 2010-11-10

Family

ID=34375580

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006527766A Expired - Fee Related JP4579246B2 (ja) 2003-09-24 2004-08-10 乳癌を診断する方法
JP2006527773A Expired - Fee Related JP4620670B2 (ja) 2003-09-24 2004-09-24 乳癌を診断する方法
JP2007237927A Withdrawn JP2008092949A (ja) 2003-09-24 2007-09-13 乳癌を診断する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006527773A Expired - Fee Related JP4620670B2 (ja) 2003-09-24 2004-09-24 乳癌を診断する方法
JP2007237927A Withdrawn JP2008092949A (ja) 2003-09-24 2007-09-13 乳癌を診断する方法

Country Status (9)

Country Link
US (3) US7531300B2 (https=)
EP (2) EP1668354A2 (https=)
JP (3) JP4579246B2 (https=)
CN (2) CN1898563B (https=)
AT (1) ATE508202T1 (https=)
DE (1) DE602004032556D1 (https=)
ES (1) ES2365732T3 (https=)
TW (2) TW200512298A (https=)
WO (2) WO2005029067A2 (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054510A2 (en) * 2003-12-05 2005-06-16 Erasmus Mc Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
EP1854473A1 (en) * 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
ES2348161T3 (es) * 2005-03-11 2010-11-30 Oncotherapy Science, Inc. Métodos para dañar células usando funciones efectoras de anticuerpos anti-gfra1.
WO2007013359A2 (en) * 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Cancer related gene rasgef1a
US8795976B2 (en) 2005-07-29 2014-08-05 Oncotherapy Science, Inc. Gene and polypeptide relating to breast cancer
JP2007037421A (ja) * 2005-08-01 2007-02-15 Osaka Univ 大腸癌リンパ節転移の有無を予測するための遺伝子セット
WO2007141595A2 (en) 2005-11-10 2007-12-13 Aurelium Biopharma Inc. Method of diagnosing breast cancer using protein markers
WO2007061770A2 (en) * 2005-11-17 2007-05-31 University Of Maryland Method and system for analysis of time-series molecular quantities
WO2007088971A1 (ja) * 2006-02-03 2007-08-09 Messengerscape Co., Ltd. がん予後判定に利用できる遺伝子群
CN101415440A (zh) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 治疗肺癌的方法
US20080108065A1 (en) * 2006-04-28 2008-05-08 Indra Poola Systems and diagnostic methods for breast cancer using mmp-1 markers
WO2008018642A2 (en) * 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
WO2008037700A2 (en) * 2006-09-27 2008-04-03 Siemens Healthcare Diagnostics Gmbh Methods for breast cancer prognosis
WO2008093427A1 (ja) * 2007-02-01 2008-08-07 Oriental Yeast Co., Ltd. 乳癌細胞の検出方法
EP2118663B1 (en) 2007-02-15 2014-04-02 Universita' Degli Studi di Torino Regulation of expression of pi3kb protein in tumors
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
CN101835892B (zh) 2007-08-20 2013-11-06 肿瘤疗法科学股份有限公司 Cdca1肽和包含cdca1肽的药剂
EP2189471B1 (en) 2007-08-20 2017-10-04 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
EP2209495A4 (en) * 2007-10-04 2012-05-02 Agency Science Tech & Res TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2009064933A2 (en) * 2007-11-13 2009-05-22 Ikonisys, Inc. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
WO2009089548A2 (en) * 2008-01-11 2009-07-16 H. Lee Moffitt Cancer & Research Institute, Inc. Malignancy-risk signature from histologically normal breast tissue
WO2009116860A1 (en) * 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20100055705A1 (en) * 2008-08-29 2010-03-04 Wilson Gerald M Compositions and methods for diagnosing and treating cancer
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
KR101174369B1 (ko) 2009-05-01 2012-08-16 한국생명공학연구원 유방암 진단용 바이오마커 및 유방암 진단제
WO2010138826A1 (en) * 2009-05-29 2010-12-02 University Of Utah Research Foundation Methods and compositions related to cellular assays
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
CA2796217A1 (en) * 2010-04-13 2011-10-20 The Trustees Of Columbia University In The City Of New York Biomarkers based on a multi-cancer invasion-associated mechanism
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
JP5866669B2 (ja) 2010-10-26 2016-02-17 国立大学法人山口大学 乳がん発症感受性の判定方法
WO2012066093A1 (en) * 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
AU2011351990A1 (en) * 2010-12-29 2013-07-18 Expression Pathology, Inc. Protein biomarkers of recurrent breast cancer
CN102312002A (zh) * 2011-09-20 2012-01-11 李艳 一种快速检测BRCA1基因mRNA表达量的试剂盒
EP2771464B1 (en) 2011-10-27 2018-03-21 Yeda Research and Development Co. Ltd. Methods of treating cancer
KR102127211B1 (ko) * 2011-10-28 2020-06-29 온코세라피 사이언스 가부시키가이샤 Ｔｏｐｋ 펩티드 및 이를 포함하는 백신
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
RU2619739C2 (ru) * 2012-05-30 2017-05-17 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Способ диагностики и прогноза при гиперпролиферативных заболеваниях молочной железы
WO2014010229A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
DK2895600T3 (da) 2012-09-11 2020-04-27 Onco Therapy Science Inc Ube2t-peptider og vacciner, der indeholder disse
AU2013368945B2 (en) * 2012-12-26 2020-01-23 Innosign B.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
DK3055429T3 (en) * 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
CA2942721A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
SG11201700839SA (en) 2014-08-04 2017-03-30 Oncotherapy Science Inc Cdca1-derived peptide and vaccine containing same
US10311681B2 (en) 2015-08-19 2019-06-04 Mark A. Litman Electronic table game platform with secondary random event displays
US10380834B2 (en) 2015-07-22 2019-08-13 Mark A. Litman Replaceable flexible electronic table top with display function for gaming tables
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
US11609427B2 (en) 2015-10-16 2023-03-21 Ostendo Technologies, Inc. Dual-mode augmented/virtual reality (AR/VR) near-eye wearable displays
US11106273B2 (en) * 2015-10-30 2021-08-31 Ostendo Technologies, Inc. System and methods for on-body gestural interfaces and projection displays
KR102475128B1 (ko) 2015-11-30 2022-12-07 (주)아모레퍼시픽 Entpd4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
KR102541256B1 (ko) 2015-11-30 2023-06-12 (주)아모레퍼시픽 Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
US10345594B2 (en) 2015-12-18 2019-07-09 Ostendo Technologies, Inc. Systems and methods for augmented near-eye wearable displays
US10578882B2 (en) 2015-12-28 2020-03-03 Ostendo Technologies, Inc. Non-telecentric emissive micro-pixel array light modulators and methods of fabrication thereof
US10353203B2 (en) 2016-04-05 2019-07-16 Ostendo Technologies, Inc. Augmented/virtual reality near-eye displays with edge imaging lens comprising a plurality of display devices
US10453431B2 (en) 2016-04-28 2019-10-22 Ostendo Technologies, Inc. Integrated near-far light field display systems
US10522106B2 (en) 2016-05-05 2019-12-31 Ostendo Technologies, Inc. Methods and apparatus for active transparency modulation
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
ES2874230T3 (es) * 2016-06-03 2021-11-04 Univ Kyushu Nat Univ Corp Proteína de fusión para mejorar la expresión de proteínas a partir de ARNm diana
EP3529387A4 (en) 2016-10-19 2020-06-10 The University of British Columbia PROCESS FOR LEACHING METAL SULPHIDES USING REAGENTS HAVING THIOCARBONYL FUNCTIONAL GROUPS
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
KR102091747B1 (ko) * 2017-11-15 2020-03-20 주식회사 프로탄바이오 유방암 진단용 바이오마커 및 이의 용도
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109234384A (zh) * 2018-10-31 2019-01-18 中国医学科学院阜外医院 Hmgcl作为诊断标志物和治疗靶点在致密化不全型心肌病的应用
SG11202106398WA (en) * 2018-11-04 2021-07-29 Pfs Genomics Inc Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN120463721A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
CN109811059B (zh) * 2019-03-31 2021-10-19 青岛泱深生物医药有限公司 生物标志物uggt1在宫颈疾病中的应用
EP4185862A4 (en) * 2020-09-14 2024-12-25 Duke University COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DYSTONIA
AU2021345381A1 (en) 2020-09-18 2023-05-04 Jetti Resources, Llc Extracting base metals using a wetting agent and a thiocarbonyl functional group reagent
CN113025720B (zh) * 2021-04-28 2022-12-27 深圳市人民医院 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用
CN113466447B (zh) * 2021-05-28 2024-03-08 天津市肿瘤医院（天津医科大学肿瘤医院） 诊断胰腺癌预后的肿瘤标志物bzw1及检测试剂盒
CN114931665B (zh) * 2021-12-14 2024-09-27 广州医科大学 六型胶原α2亚基在神经修复产品中的应用
CN114561358B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高细胞慢病毒感染率的增强感染培养基及方法
CN114561470B (zh) * 2022-03-19 2024-03-01 新乡医学院 三阴性乳腺癌分子标志物及其应用
CN115616214B (zh) * 2022-09-20 2026-03-03 湖南中医药大学 Sox10抗体的应用、试剂盒
US12366920B2 (en) 2022-09-26 2025-07-22 Pison Technology, Inc. Systems and methods for gesture inference using transformations
US12366923B2 (en) 2022-09-26 2025-07-22 Pison Technology, Inc. Systems and methods for gesture inference using ML model selection
US12340627B2 (en) 2022-09-26 2025-06-24 Pison Technology, Inc. System and methods for gesture inference using computer vision
US12502110B2 (en) 2023-10-24 2025-12-23 Pison Technology, Inc. Systems and methods for determining physiological state based on surface biopotentials
CN118243927A (zh) * 2024-04-29 2024-06-25 东莞市石碣医院 eIF3b作为乳腺癌耐药检测靶点的应用
CN119007982A (zh) * 2024-07-26 2024-11-22 大连医科大学附属第二医院 基于肿瘤浸润边缘e-tls预测非小细胞肺癌预后的方法和设备
CN119955854B (zh) * 2025-01-20 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种侏儒症小鼠模型的构建方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
BR9707125A (pt) * 1996-01-11 1999-07-20 Corixa Corp Composições e processos para o tratamento e diagnóstico de câncer de mama
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004510442A (ja) * 2000-10-03 2004-04-08 グラクソ　グループ　リミテッド 腫瘍マーカーおよび使用方法
US20030157544A1 (en) * 2000-10-30 2003-08-21 Eos Biotechnology, Inc. Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US20030104418A1 (en) * 2001-04-27 2003-06-05 Chao Zhang Diagnostic markers for breast cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
EP1856278A2 (en) 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
WO2008018642A2 (en) 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Also Published As

Publication number Publication date
ES2365732T3 (es) 2011-10-10
EP1668156A2 (en) 2006-06-14
JP2007506426A (ja) 2007-03-22
US20120010090A1 (en) 2012-01-12
WO2005029067A2 (en) 2005-03-31
US7531300B2 (en) 2009-05-12
CN1890381A (zh) 2007-01-03
DE602004032556D1 (https=) 2011-06-16
CN1890381B (zh) 2011-06-22
EP1668156B1 (en) 2011-05-04
JP4620670B2 (ja) 2011-01-26
TW200512298A (en) 2005-04-01
EP1668156B9 (en) 2012-02-22
JP2008092949A (ja) 2008-04-24
ATE508202T1 (de) 2011-05-15
EP1668354A2 (en) 2006-06-14
WO2005029067A3 (en) 2005-08-18
US8044193B2 (en) 2011-10-25
CN1898563A (zh) 2007-01-17
CN1898563B (zh) 2011-11-23
JP2007506424A (ja) 2007-03-22
WO2005028676A3 (en) 2005-09-15
US20070269432A1 (en) 2007-11-22
WO2005028676A2 (en) 2005-03-31
US20090286856A1 (en) 2009-11-19
TW200521243A (en) 2005-07-01

Similar Documents

Publication Publication Date Title
JP4579246B2 (ja) 乳癌を診断する方法
JP5109131B2 (ja) 膀胱癌を診断する方法
JP2007506425A (ja) 肝細胞癌を診断する方法
JP2006500946A (ja) 精巣精上皮腫の診断方法
US8029981B2 (en) Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma
JP2009502112A (ja) 腎細胞癌を診断および処置するための方法
US20070202109A1 (en) Method Of Diagnosing Breast Cancer
EP1786925B1 (en) Genes and polypeptides relating to breast cancers
EP1907859B1 (en) Genes and polypeptides relating to prostate cancers
EP1910570B1 (en) Gene and polypeptide relating to breast cancer
JP2007522791A (ja) 結腸直腸癌を診断する方法
JP2009505631A (ja) 癌関連遺伝子ｒａｓｇｅｆ１ａ
EP1727831A1 (en) Genes and polypeptides relating to prostate cancers

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100802

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100825

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees